Stage 2 ccRCC is localized, with tumors larger than 7 cm but no lymph node or distant metastasis involvement. Diagnosis involves imaging, laboratory tests, and occasionally biopsy, with surgery as the ...

For decades, researchers have been seeking a therapy to improve outcomes for patients with clear cell renal cell carcinoma who underwent a nephrectomy. Postsurgical immunotherapy significantly ...

Renal cell carcinoma (RCC) is one of the 10 most commonly diagnosed solid tumors. Most RCCs are histologically defined as clear cell, comprising approximately 75% of diagnoses. However, the remaining ...

Belzutifan, a hypoxia-inducible factor 2α inhibitor, showed clinical activity in clear-cell renal-cell carcinoma in early-phase studies. In a phase 3, multicenter, open-label, active-controlled trial, ...

Adjuvant pembrolizumab therapy after surgery for renal-cell carcinoma was approved on the basis of a significant improvement in disease-free survival in the KEYNOTE-564 trial. Whether the results ...

Patients with advanced clear cell RCC whose disease progressed after 1-3 prior systemic therapies (including an anti–PD- [L]1 therapy) were randomly assigned 1:1 to belzutifan 200 mg or 120 mg daily: ...